{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:05:44Z","timestamp":1648512344420},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s10096-018-3429-x","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T13:42:46Z","timestamp":1542289366000},"page":"423-426","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?"],"prefix":"10.1007","volume":"38","author":[{"given":"Jes\u00fas","family":"Troya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Montejano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Cabello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Matarranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Ca\u00f1amares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Sol\u00eds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis \u00c1lvarez-Sala","family":"Walther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,15]]},"reference":[{"key":"3429_CR1","unstructured":"European Guidelines for treatment of HIV-infected adults in Europe. Guidelines version 9.0. European AIDS Clinical Society (EACS), October, 2017. Available at: \n                    http:\/\/www.eacsociety.org\/files\/guidelines_9.0-english.pdf\n                    \n                  . (Accessed August 2018)"},{"key":"3429_CR2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services USA. Available at: \n                    https:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf.pdf\n                    \n                  . (Accessed August 2018)"},{"key":"3429_CR3","unstructured":"Raltegravir (Edurant\u00ae). Data sheet available from: \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022145s004lbl.pdf\n                    \n                   (Accessed August 2018)"},{"key":"3429_CR4","unstructured":"Rilpivirine (Issentress\u00ae). Data sheet available from: \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022145s004lbl.pdf\n                    \n                   (Accessed August 2018)"},{"issue":"3","key":"3429_CR5","doi-asserted-by":"publisher","first-page":"e32445","DOI":"10.1371\/journal.pone.0032445","volume":"7","author":"TA Rasmussen","year":"2012","unstructured":"Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, Ostergaard L, Langdahl BL, Laursen AL (2012) Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One 7(3):e32445. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0032445","journal-title":"PLoS One"},{"key":"3429_CR6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1086\/656417","volume":"51","author":"HJ Stellbrink","year":"2010","unstructured":"Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H, ASSERT Study Group (2010) Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV infected adults: 48-week results from the ASSERT study. Clin Infect Dis 51:963\u2013972. \n                    https:\/\/doi.org\/10.1086\/656417","journal-title":"Clin Infect Dis"},{"issue":"12","key":"3429_CR7","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1093\/jac\/dkw347","volume":"71","author":"A Curran","year":"2016","unstructured":"Curran A, Rojas J, Cabello A, Troya J, Imaz A, Domingo P, Martinez E, Ryan P, G\u00f3rgolas M, Podzamczer D, Knobel H, Guti\u00e9rrez F, Ribera E (2016) Effectiveness and safety of an abacavir\/lamivudine\u200a+\u200arilpivirine regimen for the treatment of HIV-1 infection in naive patients. J Antimicrob Chemother 71(12):3510\u20133514. \n                    https:\/\/doi.org\/10.1086\/656417","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"3429_CR8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","volume":"13","author":"F Raffi","year":"2013","unstructured":"Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S, extended SPRING-2 Study Group (2013) Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-na\u00efve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 13(11):927\u2013935. \n                    https:\/\/doi.org\/10.1016\/S1473-3099(13)70257-3","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"3429_CR9","doi-asserted-by":"publisher","first-page":"e0164455","DOI":"10.1371\/journal.pone.0164455","volume":"11","author":"J Troya","year":"2016","unstructured":"Troya J, Ryan P, Ribera E, Podzamczer D, Honta\u00f1\u00f3n V, Terr\u00f3n JA, Boix V, Moreno S, Barrufet P, Casta\u00f1o M, Carrero A, Galindo MJ, Su\u00e1rez-Lozano I, Knobel H, Raffo M, Sol\u00eds J, Yllescas M, Esteban H, Gonz\u00e1lez-Garc\u00eda J, Berenguer J, Imaz A (2016) Abacavir\/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 week results of the SIMRIKI retrospective study. PLoS One 11(10):e0164455. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0164455","journal-title":"PLoS One"},{"issue":"5","key":"3429_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s10096-016-2602-3","volume":"35","author":"R Palacios","year":"2016","unstructured":"Palacios R, P\u00e9rez-Hern\u00e1ndez IA, Mart\u00ednez MA, Mayorga ML, Gonz\u00e1lez-Domenech CM, Omar M, Olalla J, Romero A, Romero JM, P\u00e9rez-Camacho I, Hern\u00e1ndez-Quero J, Santos J (2016) Efficacy and safety of switching to abacavir\/lamivudine (ABC\/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART. Eur J Clin Microbiol Infect Dis 35(5):815\u2013819. \n                    https:\/\/doi.org\/10.1007\/s10096-016-2602-3","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl. 1","key":"3429_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/hiv.12393","volume":"17","author":"N Marshall","year":"2014","unstructured":"Marshall N, Hedley L, Smith C, Swaden L, Tsintas R, Edwards S, Waters L, Johnson M (2014) Is switching to Kivexa with rilpivirine as effective as switching to Eviplera in clinical practice? HIV Med 17(Suppl. 1):19. \n                    https:\/\/doi.org\/10.1111\/hiv.12393","journal-title":"HIV Med"},{"issue":"2","key":"3429_CR12","doi-asserted-by":"publisher","first-page":"e0191300","DOI":"10.1371\/journal.pone.0191300","volume":"13","author":"N Galizzi","year":"2018","unstructured":"Galizzi N, Galli L, Poli A, Gianotti N, Carini E, Bigoloni A, Tambussi G, Nozza S, Lazzarin A, Castagna A, Mancusi D, Termini R (2018) Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load. PLoS One 13(2):e0191300. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0191300","journal-title":"PLoS One"},{"issue":"11","key":"3429_CR13","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1097\/QAD.0b013e32833a608a","volume":"24","author":"E Mart\u00ednez","year":"2010","unstructured":"Mart\u00ednez E, Larrousse M, Llibre JM, Guti\u00e9rrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, P\u00e9rez I, Gatell JM, SPIRAL Study Group (2010) Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 24(11):1697\u20131707. \n                    https:\/\/doi.org\/10.1097\/QAD.0b013e32833a608a","journal-title":"AIDS"},{"key":"3429_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/00365548.2013.840920","volume":"46","author":"M Fabbiani","year":"2014","unstructured":"Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S (2014) Safety and efficacy of treatment switch to raltegravir plus tenofovir\/emtricitabine or abacavir\/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scan J Infect Dis 46:34\u201345. \n                    https:\/\/doi.org\/10.3109\/00365548.2013.840920","journal-title":"Scan J Infect Dis"},{"key":"3429_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7883\/yoken.JJID.2014.236","volume":"69","author":"A Suzuki","year":"2016","unstructured":"Suzuki A, Uehara Y, Saita M, Inui A isonuma H, Naito T (2016) Raltegravir and abacavir\/lamivudine in Japanese treatment-naive and treatment experienced patients with HIV infection: a 48-week retrospective pilot analysis. Jpn J Infect Dis 69:33\u201338. \n                    https:\/\/doi.org\/10.7883\/yoken.JJID.2014.236","journal-title":"Jpn J Infect Dis"},{"issue":"3","key":"3429_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1080\/23744235.2017.1374552","volume":"50","author":"L Galli","year":"2018","unstructured":"Galli L, Poli A, Muccini C, Galizzi N, Danise A, Spagnuolo V, Gianotti N, Carini E, Lazzarin A, Castagna A (2018) An observational, retrospective analysis evaluating switching to raltegravir plus abacavir\/lamivudine in HIV-1-infected patients: the ORASWIRAL study. Infect Dis 50(3):220\u2013222. \n                    https:\/\/doi.org\/10.1080\/23744235.2017.1374552","journal-title":"Infect Dis"},{"issue":"6","key":"3429_CR17","doi-asserted-by":"publisher","first-page":"e0198768","DOI":"10.1371\/journal.pone.0198768","volume":"13","author":"J Troya","year":"2018","unstructured":"Troya J, Montejano R, Ryan P, G\u00f3mez C, Matarranz M, Cabello A, Vera F, Sep\u00falveda MA, Santos I, Samperiz G, Bachiller P, Boix V, Barrufet P, Cervero M, Sanz J, Sol\u00eds J, Yllescas M, Valencia E, GESIDA-8715 Study Group (2018) Raltegravir plus abacavir\/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study. PLoS One 13(6):e0198768. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0198768","journal-title":"PLoS One"},{"issue":"6","key":"3429_CR18","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1124\/dmd.110.037523","volume":"39","author":"J Brian","year":"2011","unstructured":"Brian J, Collier A, Kharasch E, Whittington D, Thummel KE, Unadkat JD (2011) Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos 39(6):1070\u20131078. \n                    https:\/\/doi.org\/10.1124\/dmd.110.037523","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"3429_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1473-3099(14)70782-0","volume":"14","author":"JR Arribas","year":"2014","unstructured":"Arribas JR, Pialoux G, Gathe J, Di Perri G, Reynes J, Tebas P, Nguyen T, Ebrahimi R, White K, Piontkowsky D (2014) Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 14(7):581\u2013589. \n                    https:\/\/doi.org\/10.1016\/S1473-3099(14)70782-0","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"3429_CR20","doi-asserted-by":"publisher","first-page":"S18351","DOI":"10.7448\/IAS.15.6.18351","volume":"15","author":"D Ward","year":"2012","unstructured":"Ward D, Grant R (2012) Rilpivirine\/tenofovir\/emtricitabine fixed-dose combination is an efficacious and well-tolerated \u201cswitch\u201d regimen for patients on therapy. J Int AIDS Soc 15(4):S18351. \n                    https:\/\/doi.org\/10.7448\/IAS.15.6.18351","journal-title":"J Int AIDS Soc"},{"issue":"23","key":"3429_CR21","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.2169\/internalmedicine.55.7518","volume":"55","author":"H Arae","year":"2016","unstructured":"Arae H, Tateyama M, Nakamura H, Tasato D, Kami K, Miyagi K, Maeda S, Uehara H, Moromi M, Nakamura K, Fujita J (2016) Evaluation of the lipid concentrations after switching from antiretroviral drug tenofovir disoproxil fumarate\/emtricitabine to abacavir sulfate\/lamivudine in virologically-suppressed human immunodeficiency virus-infected patients. Intern Med 55(23):3435\u20133440. \n                    https:\/\/doi.org\/10.2169\/internalmedicine.55.7518","journal-title":"Intern Med"},{"key":"3429_CR22","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1086\/381783","volume":"189","author":"E Fontas","year":"2004","unstructured":"Fontas E, Van Leth F, Sabin CA, Friis-M\u00f8ller N, Rickenbach M, d'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD, Pradier C, Reiss P, D:A:D Study Group (2004) Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 189:1056\u20131074. \n                    https:\/\/doi.org\/10.1086\/381783","journal-title":"J Infect Dis"},{"issue":"2","key":"3429_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/15284336.2018.1455366","volume":"19","author":"M Krikke","year":"2018","unstructured":"Krikke M, Tesselaar K, van den Berk GEL, Otto SA, Freriks LH, van Lelyveld SFL, Visseren FJL, Hoepelman AIM, Arends JE (2018) The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients. HIV Clin Trials 19(2):75\u201383. \n                    https:\/\/doi.org\/10.1080\/15284336.2018","journal-title":"HIV Clin Trials"},{"key":"3429_CR24","doi-asserted-by":"publisher","unstructured":"Casado JL, Santiuste C, Vivancos MJ, Monsalvo M, Moreno A, Perez-El\u00edas MJ, Del Rey JM, Moreno S (2018) Switching to abacavir versus use of a nucleoside-sparing dual regimen for HIV-infected patients with tenofovir-associated renal toxicity. HIV Med. \n                    https:\/\/doi.org\/10.1111\/hiv.12630","DOI":"10.1111\/hiv.12630"},{"issue":"5","key":"3429_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.5414\/CP202775","volume":"55","author":"D Cattaneo","year":"2017","unstructured":"Cattaneo D, Andreoni M, Carosi G, Cauda R, Lazzarin A, Rizzardini G (2017) Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries? Int J Clin Pharmacol Ther 55(5):381\u2013393. \n                    https:\/\/doi.org\/10.5414\/CP202775","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4 Suppl3","key":"3429_CR26","doi-asserted-by":"publisher","first-page":"19497","DOI":"10.7448\/IAS.17.4.19497","volume":"17","author":"A Hill","year":"2014","unstructured":"Hill A, Hill T, Jose S, Pozniak A (2014) Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014-2018. J Int AIDS Soc 17(4 Suppl3):19497. \n                    https:\/\/doi.org\/10.7448\/IAS.17.4.19497","journal-title":"J Int AIDS Soc"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-018-3429-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-018-3429-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-018-3429-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:21:51Z","timestamp":1573777311000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-018-3429-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,15]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["3429"],"URL":"https:\/\/doi.org\/10.1007\/s10096-018-3429-x","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,15]]},"assertion":[{"value":"4 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethical approval has not been necessary as this article is based on a review of published data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent has not been necessary as this article is based on a review of published data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}